« Previous
Next »
Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 9
, Pages
1453-1461
, September 2009
A Preliminary Assessment of the Benefits of the Addition of Botulinum Toxin A to a Conventional Therapy Program on the Function of People With Longstanding Stroke
-
The mean MAL with standard deviation bars or AOU presented individually for both group 1 BTX-A/drug followed by placebo and group 2 placebo followed by BTX-A at baseline and the end of each 12-week ar
The mean MAL with standard deviation bars or AOU presented individually for both group 1 BTX-A/drug followed by placebo and group 2 placebo followed by BTX-A at baseline and the end of each 12-week arm.
-
The mean MAL with standard deviation bars for QOM presented individually for both group 1 BTX-A/drug followed by placebo and group 2 placebo followed by BTX-A at baseline and the end of each 12-week aThe mean MAL with standard deviation bars for QOM presented individually for both group 1 BTX-A/drug followed by placebo and group 2 placebo followed by BTX-A at baseline and the end of each 12-week arm.
Supported by an unrestricted grant to University of Alabama at Birmingham by Allergan Inc. Allergan was allowed to see a prior draft of this article and make comments, but the authors made all decisions regarding the final content.
A commercial party having a direct financial interest in the results of the research supporting this article has not conferred nor will confer a financial benefit on the author or one or more of the authors.
Reprints are not available from the author.
PII: S0003-9993(09)00357-8
doi: 10.1016/j.apmr.2009.02.026
© 2009 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 9
, Pages
1453-1461
, September 2009
